Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

NCT05715840 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

368

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

Interventions

DRUG: SG001 injection
DRUG: Paclitaxel
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Bevacizumab injection
DRUG: SG001 placebo

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.